Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy ACOG?
Source: Newsfilter
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.320
Low
18.00
Averages
18.00
High
18.00
Current: 5.320
Low
18.00
Averages
18.00
High
18.00
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Cognition Reports Wider Losses and Revenue Miss
- Disappointing Earnings: Alpha Cognition reported a fiscal year GAAP EPS of -$1.17, missing estimates by $0.06, indicating ongoing challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated $6.79 million in revenue, falling short of expectations by $3.89 million, reflecting unmet market demand during its transition to commercial stage, potentially leading to slowed future growth.
- Reduced R&D Spending: Research and development expenses decreased to $1.9 million from $3.9 million in fiscal year 2024, indicating a shift in resource allocation towards commercialization, which may impact long-term innovation capabilities.
- Improved Cash Position: As of December 31, 2025, the company reported cash reserves of $66.0 million, up from $48.5 million in 2024, bolstered by $40 million in net proceeds from a capital raise completed in October 2025, providing an estimated two-year runway for operations.
See More
Multiple Companies Set to Report Earnings
- Argan, Inc. Earnings Forecast: Argan, Inc. is expected to report earnings per share of $1.99 for the quarter ending January 31, 2026, reflecting a 10.36% decrease compared to the same quarter last year, indicating volatility in its profitability despite beating expectations in two other quarters over the past year.
- Oxford Industries, Inc. Performance Outlook: Oxford Industries anticipates earnings per share of only $0.05, representing a significant 96.35% decline year-over-year, highlighting severe challenges in the competitive textile industry, although the company has exceeded expectations three times in the past year.
- Veritone, Inc. Earnings Projection: Veritone is forecasting earnings per share of -$0.10, which is a 60.00% increase from the same quarter last year, yet it failed to meet consensus expectations in the first quarter of 2025, reflecting instability in its earnings potential.
- Braskem S.A. Financial Condition: Braskem is projected to report earnings per share of -$0.98, a staggering 151.28% decrease compared to the same quarter last year, indicating ongoing difficulties in the chemical sector, and it missed consensus expectations in the fourth quarter of 2024, underscoring persistent pressure on its profitability.
See More
Solas Capital Management Acquires Stake in Euronet Worldwide
- New Investment Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Euronet Worldwide by acquiring 73,494 shares valued at $5.59 million at quarter-end, reflecting confidence in the company's growth potential despite recent stock performance.
- Ownership Analysis: This investment represents 3.17% of Solas Capital Management's reportable AUM in its 13F filing, indicating a strategic diversification approach, even as Euronet's stock has declined by 30% over the past year.
- Company Performance Overview: Euronet Worldwide reported $4.24 billion in revenue for 2025, a 6% year-over-year increase, with net income reaching $309 million, showcasing robust fundamentals despite stock underperformance in the competitive payments processing sector.
- Future Growth Expectations: Management anticipates adjusted earnings per share to grow by 10% to 15% in 2026, aligning with trends in digital money transfers and international payment expansions, which may attract further investor interest in the company.
See More
Alpha Cognition Schedules Q4 2025 Earnings Call
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q4 and full-year 2025 financial results on March 26, 2026, at 4:30 PM ET, demonstrating the company's commitment to transparency and timely updates for stakeholders.
- Conference Call Details: Following the earnings release, management will host a conference call, allowing participants to dial in at 1-877-407-9039 or 1-201-689-8470, ensuring investors receive the latest company insights promptly.
- Access to Financial Results: The company will publish its financial results and business highlights on its website, enhancing investor understanding of its financial health and potentially boosting market confidence.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight the company's expectations and potential risks, indicating a cautious approach in navigating uncertain market conditions.
See More
Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
See More
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
Alpha Cognition Reports Wider Losses and Revenue Miss
- Disappointing Earnings: Alpha Cognition reported a fiscal year GAAP EPS of -$1.17, missing estimates by $0.06, indicating ongoing challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated $6.79 million in revenue, falling short of expectations by $3.89 million, reflecting unmet market demand during its transition to commercial stage, potentially leading to slowed future growth.
- Reduced R&D Spending: Research and development expenses decreased to $1.9 million from $3.9 million in fiscal year 2024, indicating a shift in resource allocation towards commercialization, which may impact long-term innovation capabilities.
- Improved Cash Position: As of December 31, 2025, the company reported cash reserves of $66.0 million, up from $48.5 million in 2024, bolstered by $40 million in net proceeds from a capital raise completed in October 2025, providing an estimated two-year runway for operations.
See More
Multiple Companies Set to Report Earnings
- Argan, Inc. Earnings Forecast: Argan, Inc. is expected to report earnings per share of $1.99 for the quarter ending January 31, 2026, reflecting a 10.36% decrease compared to the same quarter last year, indicating volatility in its profitability despite beating expectations in two other quarters over the past year.
- Oxford Industries, Inc. Performance Outlook: Oxford Industries anticipates earnings per share of only $0.05, representing a significant 96.35% decline year-over-year, highlighting severe challenges in the competitive textile industry, although the company has exceeded expectations three times in the past year.
- Veritone, Inc. Earnings Projection: Veritone is forecasting earnings per share of -$0.10, which is a 60.00% increase from the same quarter last year, yet it failed to meet consensus expectations in the first quarter of 2025, reflecting instability in its earnings potential.
- Braskem S.A. Financial Condition: Braskem is projected to report earnings per share of -$0.98, a staggering 151.28% decrease compared to the same quarter last year, indicating ongoing difficulties in the chemical sector, and it missed consensus expectations in the fourth quarter of 2024, underscoring persistent pressure on its profitability.
See More
Solas Capital Management Acquires Stake in Euronet Worldwide
- New Investment Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Euronet Worldwide by acquiring 73,494 shares valued at $5.59 million at quarter-end, reflecting confidence in the company's growth potential despite recent stock performance.
- Ownership Analysis: This investment represents 3.17% of Solas Capital Management's reportable AUM in its 13F filing, indicating a strategic diversification approach, even as Euronet's stock has declined by 30% over the past year.
- Company Performance Overview: Euronet Worldwide reported $4.24 billion in revenue for 2025, a 6% year-over-year increase, with net income reaching $309 million, showcasing robust fundamentals despite stock underperformance in the competitive payments processing sector.
- Future Growth Expectations: Management anticipates adjusted earnings per share to grow by 10% to 15% in 2026, aligning with trends in digital money transfers and international payment expansions, which may attract further investor interest in the company.
See More
Alpha Cognition Schedules Q4 2025 Earnings Call
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q4 and full-year 2025 financial results on March 26, 2026, at 4:30 PM ET, demonstrating the company's commitment to transparency and timely updates for stakeholders.
- Conference Call Details: Following the earnings release, management will host a conference call, allowing participants to dial in at 1-877-407-9039 or 1-201-689-8470, ensuring investors receive the latest company insights promptly.
- Access to Financial Results: The company will publish its financial results and business highlights on its website, enhancing investor understanding of its financial health and potentially boosting market confidence.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight the company's expectations and potential risks, indicating a cautious approach in navigating uncertain market conditions.
See More
Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
See More
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
